ArticleJournal of racial and ethnic health disparities2026
A Real-World Evaluation of Racial Disparities in the Receipt of Cancer Treatments and Anthracycline-Based Chemotherapies in Early-Stage Breast Cancer Patients.
Article in Journal of racial and ethnic health disparities, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundResearch studies have demonstrated that cardiotoxicity due to cancer treatments may be more prevalent in Black and other racial minority breast cancer (BC) patients. Our study examined racial disparities in receipt of BC treatments, with a focus on therapies associated with cardiotoxicity.
methodsThe study population included 12,350 female BC patients who were diagnosed with early-stage BC between January 1, 2011, and January 18, 2023, from an electronic health record-derived database. Odds ratios (ORs) and 95% confidence intervals (CI) were estimated using multivariable logistic regressions for the associations between race (Asian, Black/African American (AA), Other, White) and receipt of radiation and chemotherapy. A sensitivity analysis was conducted among 4,318 women who received chemotherapy to assess racial disparities in anthracycline use (chemotherapeutic agents known to be associated with cardiotoxicity).
resultsWhile most women received radiation (61.9%), only 35% received chemotherapy in the early-stage setting (of which 41.5% were anthracycline-based regimens). Black/AA women were more likely prescribed anthracycline-based chemotherapy than not (50.4%) compared to all other racial groups (White: 39.2%, Asian: 38.3%, Other: 44.7%). No significant associations were observed between race and radiation. We identified a racial disparity among other race women, who had a 21% (95% CI: 1.05, 1.40) higher odds of receiving chemotherapy than White women. Among women who received chemotherapy, no racial disparities were observed for receiving anthracyclines after adjusting for sociodemographic and tumor characteristics.
conclusionsOur findings provide detailed real-world evidence on treatments among diverse BC patients. Future research should elucidate if treatment inequities drive cardiotoxic disparities.
Indexed as
Identifiers
41543786What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.